Alan Cheng

Dr. Alan Cheng

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2007 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ACAlan Cheng
Alan Cheng
RCRyan G Coleman
Ryan G Coleman
KSKathleen T Smyth
Kathleen T Smyth
QCQing Cao
Qing Cao
PSPatricia Soulard
Patricia Soulard
EHEnoch S Huang
Enoch S Huang

1 December 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SCSean Caenepeel
Sean Caenepeel
SBSean P. Brown
Sean P. Brown
BBBrian Belmontes
Brian Belmontes
GMGordon Moody
Gordon Moody
KKKathleen S. Keegan
Kathleen S. Keegan
PHPaul E. Hughes
Paul E. Hughes
The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer. To overcome the significant challenges associated with inhibition of MCL1 protein–protein interactions, we rigorously applied small-molecule conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans. We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematologic cancer cell lines, tumor xenograft models, and primary patient samples. With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by reductions in B cells, monocytes, and neutrophils. Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses. These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics. Significance: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies. The synergistic combination of AMG 176 and venetoclax demonstrates robust activity in models of AML at tolerated doses, highlighting the promise of BH3-mimetic combinations in hematologic cancers. See related commentary by Leber et al., p. 1511. This article is highlighted in the In This Issue feature, p. 1494

14 April 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EFEvan N. Feinberg
Evan N. Feinberg
EJElizabeth M Joshi
Elizabeth M Joshi
VPVijay S. Pande
Vijay S. Pande
ACAlan Cheng
Alan Cheng

1 April 2003 in Journal of Molecular Biology
Verified
Journal Article
Closed access
ACAlan Cheng
Alan Cheng
WCWilliam W. Chen
William W. Chen
CFCynthia N. Fuhrmann
Cynthia N. Fuhrmann
AFAlan D. Frankel
Alan D. Frankel

27 April 2007 in Biochemistry
Verified
Journal Article
Closed access
MKMichael Kothe
Michael Kothe
DKDarcy Kohls
Darcy Kohls
SLSimon Low
Simon Low
RCRocco Coli
Rocco Coli
ACAlan Cheng
Alan Cheng
YDYuan-Hua Ding
Yuan-Hua Ding

11 September 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
JAJeremy R. Ash
Jeremy R. Ash
CWCas Wognum
Cas Wognum
RRRaquel Rodríguez-Pérez
Raquel Rodríguez-Pérez
MAMatteo Aldeghi
Matteo Aldeghi
ACAlan Cheng
Alan Cheng
WWW. Patrick Walters
W. Patrick Walters